Gino has over a decade of board leadership and governance expertise in both public and private global corporations. He has served as an advisor and board director to European and US venture capital, pharmaceutical, and biotechnology companies since 2011, when he stepped down from executive responsibility at Eli Lilly & Company.
During his director tenure across more than ten boards, Gino has honed his governance experience as chairman, lead independent director, and in multiple committee chair roles. He has played a leading role in several M&A transactions and has significant expertise in advising on commercial partnerships. Gino currently serves as a lead independent director for Collegium Pharmaceuticals (NASDAQ: COLL) and on several private company boards.
Gino left Eli Lilly & Company as Senior Vice President of Corporate Strategy and Business Development in 2011, after a successful 27-year career. In this capacity, he was responsible for overseeing the acquisitions of Imclone (2009), Icos (2008), and several other pipeline projects. He was a member of the Executive Committee from 2004 until his departure from the company.
Gino holds a degree in Mechanical Engineering from the University of Bologna and a Master of Business Administration from the Simon School of Business, University of Rochester.
What is Gino Santini's net worth?
The estimated net worth of Gino Santini is at least $4.46 million as of August 15th, 2025. Santini owns 95,042 shares of Collegium Pharmaceutical stock worth more than $4,459,371 as of February 5th. This net worth evaluation does not reflect any other investments that Santini may own. Learn More about Gino Santini's net worth.
How do I contact Gino Santini?
Has Gino Santini been buying or selling shares of Collegium Pharmaceutical?
Gino Santini has not been actively trading shares of Collegium Pharmaceutical during the last quarter. Most recently, Gino Santini sold 5,405 shares of the business's stock in a transaction on Friday, August 15th. The shares were sold at an average price of $37.19, for a transaction totalling $201,011.95. Following the completion of the sale, the director now directly owns 95,042 shares of the company's stock, valued at $3,534,611.98. Learn More on Gino Santini's trading history.
Who are Collegium Pharmaceutical's active insiders?
Collegium Pharmaceutical's insider roster includes Rita Balice-Gordon (Director), Garen Bohlin (Director), Joseph Ciaffoni (CEO), Joseph Ciaffoni (Pres), Scott Dreyer (EVP), John Freund (Director), Michael Heffernan (Director), Shirley Kuhlmann (EVP), Gino Santini (Director), Thomas Smith (EVP), Colleen Tupper (CFO), and Colleen Tupper (Exec. VP & CFO ). Learn More on Collegium Pharmaceutical's active insiders.
Are insiders buying or selling shares of Collegium Pharmaceutical?
During the last year, insiders at the specialty pharmaceutical company sold shares 15 times. They sold a total of 195,336 shares worth more than $6,856,675.54. The most recent insider tranaction occured on December, 8th when EVP Scott Dreyer sold 17,600 shares worth more than $847,792.00. Insiders at Collegium Pharmaceutical own 2.5% of the company.
Learn More about insider trades at Collegium Pharmaceutical. Information on this page was last updated on 12/8/2025.
